Purple Biotech Ltd

Equities

PPBT

IL0007650166

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 07:30:38 2024-04-25 am EDT			5-day change	1st Jan Change
21.3 ^ILa	+5.97%		+17.68%	-33.23%

Apr. 25	Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	CI
Mar. 14	Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	CI

Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023

March 05, 2024 at 07:59 am EST

Purple Biotech Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 19.88 million compared to USD 21.67 million a year ago.

Latest news about Purple Biotech Ltd

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	Apr. 25	CI
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	Mar. 14	CI
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	Feb. 27	CI
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	Feb. 01	CI
Purple Biotech Ltd. Announces Executive Changes	Dec. 20	CI
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	Dec. 14	CI
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 21	CI
Purple Biotech Closes $5 Million Registered Direct Offering	23-10-19	MT
Purple Biotech Reports Potential Biomarker Data Support CM24?s Mechanism of Action	23-10-06	CI
Purple Biotech Reports Positive Interim Results From Study of NT219 Cancer Treatment Candidate	23-10-03	MT
Purple Biotech Ltd. Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer	23-10-03	CI
HC Wainwright Adjusts Price Target on Purple Biotech to $9 From $7, Maintains Buy Rating	23-08-31	MT
Purple Biotech Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
JonesTrading Initiates Purple Biotech With Buy Rating, $8 Price Target	23-07-21	MT
Purple Biotech Reports Results of Dose Escalation Trial of CM24 in Advanced Pancreatic Cancer; Shares Fall	23-07-11	MT
Purple Biotech Ltd. Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients	23-07-11	CI
Top Premarket Gainers	23-07-07	MT
Purple Biotech Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Purple Biotech : Launches Trial of Monoclonal Antibody CM24 in Advanced Cancer Patients	21-04-23	MT
Purple Biotech : Launches Phase 1b/2 Study of CM24 With Bristol's Opdivo	21-03-19	DJ
Purple Biotech : Commences Phase 1b/2 Clinical Trial of CM24 in Multiple Advanced Cancers	21-03-19	MT
Purple Biotech : Kitov Changes Name to Purple Biotech	20-12-10	MT
Kitov Pharmaceuticals Holdings Ltd. Submits New Drug Application to FDA for KIT-302	17-07-31	CI

Chart Purple Biotech Ltd

Duration

Period

More charts

Company Profile

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PURPLE BIOTECH LTD	-33.23%	14.83M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs